Colistin for the treatment of urinary tract infections caused by extremely drug-resistant Pseudomonas aeruginosa: a call for a dose update

OBJECTIVES: Optimal dosage regimens of colistin for the treatment of urinary tract infections (UTI) are unknown. Colistimethate sodium (CMS), the inactive prodrug of colistin, is mainly excreted in urine and converts to colistin after filtration by glomeruli, suggesting that concentrations of colist...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Infect
Autors principals: Sorlí, Luisa, Luque, Sonia, Li, Jian, Campillo, Núria, Danés, Marc, Montero, Milagro, Segura, Concha, Grau, Santiago, Horcajada, Juan Pablo
Format: Artigo
Idioma:Inglês
Publicat: 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7265153/
https://ncbi.nlm.nih.gov/pubmed/31265867
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jinf.2019.06.011
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars